Shares are trading at 86 percent below what they went for in Avalanche's $163 million second offering, building on a $102 million IPO the year before, because the macular-degeneration treatment it had hyped was a total bust, shareholders claim.
Categories:Uncategorized
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.